Document |
Document Title |
JP2732887B2 |
PURPOSE:To bring the size of a rectifying device close to hyperfine size at a molecular level by forming a rectifying section of a first oxidation-reduction substance film composed of a flavin derivative and a second oxidation-reduction ...
|
JP2727127B2 |
|
JP2711828B2 |
To obtain tetrahydrobiopterin hydrochloride useful for medicines, etc., in a high asymmetric synthesis degree in a high purity and in a high yield by catalytically reducing erythrobiopterin, etc., in the presence of an amine compound and...
|
JPH10500949A |
The invention provides novel pteridine nucleotides which are highly fluorescent under physiological conditions and which may be used in the chemical synthesis of fluorescent oligonucleotidcs. The invention further provides for fluorescen...
|
JPH09309832A |
To obtain a therapeutic medicine effective for uveitis, especially endogenous uveitis, by using a specific methotrexate derivative as an active ingredient. This medicine for treating uveitis contains one or more kinds of a compound of fo...
|
JP2674707B2 |
|
JPH09510989A |
A stable aqueous solution of folinic acid of up to about 400 mg/ml, which does not crystallize at refridgeration temperatures, is obtained by preparing an aqueous solution of sodium folinate.
|
JPH09510695A |
Disclosed is a method of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma or hypoglycemia. The method comprises administering to an animal a compound of the formula: hereof; wherein n is zero or 1; R4, R5...
|
JP2621925B2 |
Pteridines of general formula (I): in which Y and Z, which can be identical or different, are hydrogen, OH or NH2, and X1 and X2, which can be identical or different, are hydrogen, OH, C1-C4 alkyl, phenyl, hydroxymethyl or carboxyl, for ...
|
JPH09505804A |
Flavins and their derivatives are useful for administration to mammalian subjects as an anti-viral agents, Riboflavin and riboflavin derivatives are particularly preferred for use in the treatment of HIV infection.
|
JPH09505822A |
Disclosed is the use of one or more compounds selected from the group of L-arginine, L-ornithine and L-citrulline or their salts, acid addition salts, esters or amides, as needed with the addition of folic acid or its salts and/or one or...
|
JPH09121882A |
To efficiently obtain folio acid useful as a medicine (raw material), a reinforcing agent for modified milk powder, a feed additive, an additive for culturing microorganisms, etc., by culturing a yeast having a folic acid-producing abili...
|
JPH09121881A |
To efficiently obtain folic acid useful as a medicine, a raw material for medicines, a reinforcing agent for modified milk powder, a feed additive, an additive for culturing microorganisms, etc., by culturing a microorganism having an ab...
|
JPH09504505A |
PCT No. PCT/EP94/00632 Sec. 371 Date Nov. 2, 1995 Sec. 102(e) Date Nov. 2, 1995 PCT Filed Mar. 3, 1994 PCT Pub. No. WO94/21636 PCT Pub. Date Sep. 29, 1994Pterin derivatives having the general formula I I wherein R1 represents a group -(C...
|
JP2598609B2 |
PURPOSE: To provide a 2-aminodisubstituted alkylaminopyrimidine derivative which gives 6,6-disubstituted pteridine derivative closely related-to 6,6- disubstituted tetrahydropteridines having thymidylate synthetase inhibiting activities....
|
JP2588363B2 |
PURPOSE: To provide the compounds in high yields by adding an acid to a (6RS)-diasteroisomeric mixture of an alkali metal salt of 5,6,7,8-tetrahydrofolic acid and selectively crystallizing. CONSTITUTION: By adding a small amount of an ac...
|
JP2588191B2 |
|
JP2579441B2 |
PURPOSE: To obtain a liposome preparation capable of being stored for a long period without leaking an inner encapsulated ingredient from the liposome and capable of being rehydrated on its use. CONSTITUTION: The characteristics of this ...
|
JP2579442B2 |
PURPOSE: To obtain a dehydrated liposome preparation capable of being stored for a long period without leading an inner capsulated ingredient from the liposome and capable of being rehydrated on its use. CONSTITUTION: This method for deh...
|
JP2575781B2 |
|
JP2574999B2 |
PURPOSE: To obtain the subject liposome preparation capable of being stored for a long period. CONSTITUTION: This pharmaceutical preparation comprises a liposome encapsulating an antitumor agent therein and dehydrated by a method except ...
|
JP2572553B2 |
PURPOSE: To provide a method for efficiently loading a medicine into liposomes and producing the liposomes good in storage storability. CONSTITUTION: This method for loading ionizable antitumor agents into liposomes comprises (a) the ste...
|
JP2572554B2 |
PURPOSE: To provide a method for reducing the release rate of a medicine from liposome and decreasing the administration dose and number of the medicine. CONSTITUTION: This method for reducing the release rate of an ionizable biologicall...
|
JP2567639B2 |
|
JP2567638B2 |
|
JP2567637B2 |
|
JP2564586B2 |
Novel therapeutic antibody conjugates comprising amine derivatives of folic acid analogs covalently attached via a reactive amine group to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. The conjugates ...
|
JPH08325150A |
PURPOSE: To obtain a methotrexate derivative-containing medicine effective for glomerular nephritis and autoimmunity diseases such as systemic lupus erythematosus. CONSTITUTION: A methotrexate derivative-containing medicine contains a co...
|
JPH08256786A |
To obtain riboflavin having acceptable quality suitable for the purpose of its subsequent uses through recovering and purifying riboflavin contained in fermentation broth which is produced by the method of fermentation, i.e., is produced...
|
JP2536973B2 |
A process for the preparation of free-flowing, dust- and binder-free riboflavine spray granulates or microgranulates from finely divided pure riboflavine, characterised in that an aqueous or water-containing suspension of the pure finely...
|
JP2529092B2 |
PURPOSE: To synthesize the compound for the treatment of Parkinson's disease or the like by oxidizing a 6-(2-amino-2,2-disubstituted ethylamino)-5-amino- pyrimidine to form an 5-imine and then condensing it after hydrolysis. CONSTITUTION...
|
JP2525965B2 |
PURPOSE: To provide the subject novel compounds useful as anti-tumor drugs. CONSTITUTION: The compound of formula (wherein X represents a nitrogen- containing base) in a form of (6RS)-diastereoisomer mixture, or single (6R)- or (6S)-dias...
|
JPH08505877A |
Novel compounds of formula (I) wherein n is 0 to 2; A is sulfur, CH2, oxygen, -NH- or selenium, provided that when n is 0, A cannot be CH2, and when n is 1, A cannot be CH2 or NH; X is at least one substituted or unsubstituted C1-C3 alky...
|
JPH08504798A |
The use of a compound which binds at the tetrahydrobiopterin site of NO synthase for the treatment of conditions where there is an advantage in inhibiting neuronal NO synthase with little or no inhibition of endothelial NO synthase is di...
|
JPH0829109B2 |
Process for producing microbially prepared riboflavin in the form of spray or microgranules which are free-flowing and non-dusting as feed additive by removing water from the discharge from microbial fermentations for preparing riboflavi...
|
JPH0826022B2 |
The invention relates to a new process for the preparation of 5,10-methenyl-(6R)-, 5-formyl-(6S)- and/or 5-methyl-(6S)- tetrahydrofolic acid and of their salts, characterised in that an acid addition salt or the internal salt of 5,10-met...
|
JPH0818973B2 |
Dehydrated liposomes are prepared by drying liposome preparations under reduced pressure in the presence of one or more protective sugars, e.g., the disaccharides trehalose and sucrose. Preferably, the protective sugars are present at bo...
|
JPH08501564A |
Compounds comprise epoxide-substituted alkyl side chain (R) bonded to a core moiety, comprising Core moiety (I), wherein n is an integer from about 4 to about 16 and j is an integer from about 0 to about 12, including resolved enantiomer...
|
JPH08501533A |
PCT No. PCT/HU93/00016 Sec. 371 Date Aug. 16, 1995 Sec. 102(e) Date Aug. 16, 1995 PCT Filed Mar. 18, 1993 PCT Pub. No. WO94/02148 PCT Pub. Date Feb. 3, 1994The invention relates to a pharmaceutical composition for treating the symptoms o...
|
JPH089618B2 |
The invention relates to a process for preparing (6S)-folinic acid and its salts by recrystallization of alkaline-earth salts of (6R,S)-folinic acid and, where necessary, liberation of the acid from the alkaline-earth folinates and/or, w...
|
JPH089619B2 |
Diastereomers of 10-alkyl-10-deazaminopterins are provided, as well as a synthesis for their preparation as the individual d,L. and l,L.-diastereomers, the d,L-10-ethyl diastereomer being three times as potent against L1210 cells as the ...
|
JPH0826998A |
PURPOSE: To attenuate lung capillary leak without providing undesirable effect on antitumor efficiency of interleukin-2 by administering methotrexate to mammals. CONSTITUTION: A composition of a dosage unit form containing methotrexate o...
|
JPH082902B2 |
|
JPH082903B2 |
A process for the purification of riboflavin prepared by fermentation, which is characterised in that the contaminated riboflavin is suspended in water or in dilute aqueous acid and the suspension is heated with stirring to temperatures ...
|
JPH07112968B2 |
Methods for encapsulating ionizable antineoplastic agents in liposomes using transmembrane potentials. Trapping efficiencies approaching 100% and rapid loading are readily achieved. Dehydration protocols which allow liposomes to be conve...
|
JPH07107064B2 |
|
JPH07291864A |
PURPOSE: To obtain the subject therapeutic agent, containing leucovorin as an active ingredient and capable of manifesting the reducing actions on the yellowness as an internal treatment in place of the surgical percutaneous transhepatic...
|
JPH0791190B2 |
This invention relates to the use of 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in the preparation of pharmaceutical compositions in controlled-release form which are active in ...
|
JPH0776221B2 |
The use of 6, 6-disubstituted pteridines to regulate enzymes, for example, in the treatment of Parkinson's Disease, is disclosed along with a general method of synthesizing these compounds.
|
JPH0774206B2 |
Compounds of the formula I or salts thereof (I) where R1 is ethyl, propyl or isopropyl, R2 is halogen, NO2, CF3, CN, alkyl, alkoxy, alkylthio or alkoxycarbonyl, n is 0, 1, 2 or 3, Y is O or S, R3 is hydrogen, alkyl, alkenyl, alkynyl or a...
|